PubMed

Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice.

Kim SJ, Nian C, Doudet DJ, McIntosh CH.

Diabetes. 2008 May;57(5):1331-9. Epub 2008 Feb 25.PMID: 18299314 [PubMed - indexed for MEDLINE]Related articlesFree article

Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation.

Kim SJ, Nian C, Doudet DJ, McIntosh CH.

Diabetes. 2009 Mar;58(3):641-51. Epub 2008 Dec 10.PMID: 19073764 [PubMed - indexed for MEDLINE]Related articlesFree article

Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.

Mu J, Woods J, Zhou YP, Roy RS, Li Z, Zycband E, Feng Y, Zhu L, Li C, Howard AD, Moller DE, Thornberry NA, Zhang BB.

Diabetes. 2006 Jun;55(6):1695-704.PMID: 16731832 [PubMed - indexed for MEDLINE]Related articlesFree article

Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.

Pospisilik JA, Martin J, Doty T, Ehses JA, Pamir N, Lynn FC, Piteau S, Demuth HU, McIntosh CH, Pederson RA.

Diabetes. 2003 Mar;52(3):741-50.PMID: 12606516 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.

Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Snyder K, Hilliard D, Tanen M, Cilissen C, De Smet M, de Lepeleire I, Van Dyck K, Wang AQ, Zeng W, Davies MJ, Tanaka W, Holst JJ, Deacon CF, Gottesdiener KM, Wagner JA.

J Clin Endocrinol Metab. 2006 Nov;91(11):4612-9. Epub 2006 Aug 15.PMID: 16912128 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice.

Liu X, Harada N, Yamane S, Kitajima L, Uchida S, Hamasaki A, Mukai E, Toyoda K, Yamada C, Yamada Y, Seino Y, Inagaki N.

Life Sci. 2009 Jun 19;84(25-26):876-81. Epub 2009 Apr 7.PMID: 19358859 [PubMed - indexed for MEDLINE]Related articles

Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.

Pratley RE, Salsali A.

Curr Med Res Opin. 2007 Apr;23(4):919-31. Review.PMID: 17407649 [PubMed - indexed for MEDLINE]Related articles

A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.

Green BD, Gault VA, O'Harte FP, Flatt PR.

Diabetes Obes Metab. 2005 Sep;7(5):595-604.PMID: 16050953 [PubMed - indexed for MEDLINE]Related articles

Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes.

Gallwitz B.

Drugs Today (Barc). 2007 Jan;43(1):13-25. Review.PMID: 17315049 [PubMed - indexed for MEDLINE]Related articles

Acute dipeptidyl peptidase-4 inhibition rapidly enhances insulin-mediated suppression of endogenous glucose production in mice.

Duez H, Smith AC, Xiao C, Giacca A, Szeto L, Drucker DJ, Lewis GF.

Endocrinology. 2009 Jan;150(1):56-62. Epub 2008 Sep 18.PMID: 18801896 [PubMed - indexed for MEDLINE]Related articles

Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update).

Gallwitz B.

Drugs Today (Barc). 2007 Nov;43(11):801-14. Review.PMID: 18174966 [PubMed - indexed for MEDLINE]Related articles

Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.

Green BD, Irwin N, Duffy NA, Gault VA, O'harte FP, Flatt PR.

Eur J Pharmacol. 2006 Oct 10;547(1-3):192-9. Epub 2006 Jul 27.PMID: 16945366 [PubMed - indexed for MEDLINE]Related articles

Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.

D'Alessio DA, Denney AM, Hermiller LM, Prigeon RL, Martin JM, Tharp WG, Saylan ML, He Y, Dunning BE, Foley JE, Pratley RE.

J Clin Endocrinol Metab. 2009 Jan;94(1):81-8. Epub 2008 Oct 28.PMID: 18957505 [PubMed - indexed for MEDLINE]Related articles

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.

Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA.

Clin Ther. 2006 Jan;28(1):55-72.PMID: 16490580 [PubMed - indexed for MEDLINE]Related articles

KR-62436, 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile, is a novel dipeptidyl peptidase-IV (DPP-IV) inhibitor with anti-hyperglycemic activity.

Kim KR, Rhee SD, Kim HY, Jung WH, Yang SD, Kim SS, Ahn JH, Cheon HG.

Eur J Pharmacol. 2005 Jul 25;518(1):63-70.PMID: 16106524 [PubMed - indexed for MEDLINE]Related articles

Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice.

Lamont BJ, Drucker DJ.

Diabetes. 2008 Jan;57(1):190-8. Epub 2007 Oct 10.PMID: 17928394 [PubMed - indexed for MEDLINE]Related articlesFree article

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.

Neumiller JJ.

J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S16-29. Review.PMID: 19801361 [PubMed - indexed for MEDLINE]Related articlesFree article

Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.

Moritoh Y, Takeuchi K, Hazama M.

J Pharmacol Exp Ther. 2009 May;329(2):669-76. Epub 2009 Feb 10.PMID: 19208898 [PubMed - indexed for MEDLINE]Related articles

beta-cell failure in diabetes and preservation by clinical treatment.

Wajchenberg BL.

Endocr Rev. 2007 Apr;28(2):187-218. Epub 2007 Mar 12. Review.PMID: 17353295 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1.

Duffy NA, Green BD, Irwin N, Gault VA, McKillop AM, O'Harte FP, Flatt PR.

Eur J Pharmacol. 2007 Jul 30;568(1-3):278-86. Epub 2007 May 13.PMID: 17573070 [PubMed - indexed for MEDLINE]Related articles